A Look at Jazz Pharmaceuticals (JAZZ) Valuation Following Strong Earnings, Guidance Boost, and Modeyso Approval

Jazz Pharmaceuticals (JAZZ) has drawn fresh attention after reporting strong third-quarter earnings, revising its 2025 guidance, and confirming FDA approval for Modeyso in a challenging brain tumor indication.

See our latest analysis for Jazz Pharmaceuticals.

Jazz Pharmaceuticals’ momentum has picked up steam in recent months, driven by robust third-quarter earnings, higher financial guidance for 2025, and the FDA’s accelerated approval for Modeyso in a difficult brain cancer indication. Despite these tailwinds, the 1-year total shareholder return sits at 7.4% and longer-term total returns remain slightly negative. However, the 90-day share price return of 17.5% hints that optimism could be building as new approvals and pipeline data roll out.

If Jazz’s recent surge on breakthrough approvals has you thinking about other opportunities in healthcare, it could be the perfect time to explore See the full list for free.

With shares still trading at a sizable discount to analyst targets despite recent momentum, investors must ask whether Jazz Pharmaceuticals is undervalued based on its growth prospects or if future success is already fully reflected in the stock price.

Most Popular Narrative: 26.5% Undervalued

Jazz Pharmaceuticals' most closely watched narrative suggests a fair value well above the latest closing price. This has raised eyebrows among investors who are looking for upside. The market's muted response is in sharp contrast with what these expectations imply for the years ahead.

Ongoing investments in R&D, commercialization infrastructure, and international launches (such as rolling out Ziihera in BTC across Europe) are lowering barriers to entry in new geographies as healthcare access expands. This positions Jazz for steady long-term market share and revenue growth.

Read the complete narrative.

Curious what bold financial bets underpin this narrative's valuation? It’s not just pipeline hype; there are striking growth projections beneath the surface. Dive in to discover which numbers could drive a major market rerating.

Result: Fair Value of $186.47 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, patent expirations and increased generic competition could still threaten Jazz’s growth outlook and put pressure on future profit margins.

Find out about the key risks to this Jazz Pharmaceuticals narrative.

Build Your Own Jazz Pharmaceuticals Narrative

If you see things differently or want to dig into the details yourself, you can build your own perspective in just a few minutes, and Do it your way

A great starting point for your Jazz Pharmaceuticals research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.

Looking for More Investment Ideas?

Why limit your search to one sector? Take charge of your financial future and spot fresh opportunities with Simply Wall Street’s powerful tools before other investors catch on.

• Generate income through potential market upswings by researching these 3575 penny stocks with strong financials with strong financial foundations and high upside potential.
• Tap into the smart-money world of automation and learning by scanning these 25 AI penny stocks, featuring companies at the forefront of artificial intelligence.
• Secure attractive returns from steady payouts by checking out these 15 dividend stocks with yields > 3%, which includes stocks with yields above 3% and robust fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com